Clinical Trials Browser

Neoplasm Metastasis × niraparib × Clear all

NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

Neoplasm Metastasis

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

Phase 2 Active not recruiting

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

Neoplasm Metastasis

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma